ArticlePakistan journal of medical sciences2025
Bridging conventional clinical tests and advanced biomarkers for the early diagnosis of kidney disease progression.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate and validate the applicability and reliability of seven biomarkers for the early detection of kidney diseases in the Pakistani population. Methodology: A case-control study involving two hundred participants was conducted at Nishtar and Ibn-e-Siena Hospitals, Multan, from January to December 2022. Seven serum biomarkers, klotho, uromodulin, neutrophil gelatinase-associated lipocalin (NGAL), beta-2 microglobulin, asymmetric dimethyl arginine (ADMA), beta trace protein, and fetuin-A, were exploited, and their levels were measured by enzyme-linked immunosorbent assay (ELISA) kits. Diagnostic performance of these biomarkers was measured through the receiver-operator curve (ROC) via GraphPad Prism. Correlations among biomarkers were assessed by matrix scatter plots, while protein-protein interactions were analyzed using STRING. Data was statistically analyzed using one-way analysis of variance (ANOVA) and the Tukey's multiple comparison test. Results: The results demonstrated a significantly reduced eGFR and elevated creatinine levels in chronic kidney disease (CKD) and acute kidney injury (AKI) patients compared to controls. Additionally, all seven diagnostic serum biomarkers were found to be associated with CKD. Uromodulin level was lower in AKI (35ng/ml ±3.8) verses CKD (41.7ng/ml±14.3) patients, while other biomarkers were significantly higher in AKI. Receiver-operator curve (ROC) analysis showed excellent CKD detection, particularly by BTP, NGAL, B2M, ADMA, and uromodulin (AUC>0.99). Furthermore, klotho correlated positively with several biomarkers, while uromodulin had negative correlations, and NGAL showed strong positive correlations overall. STRING results revealed strong interactions among B2M biomarker with uromodulin. Conclusions: The BTP, ADMA, and Klotho show good potential for improving early diagnosis and differentiation of CKD and AKI, supporting timely and clinical interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.